ReviewCurrent gastroenterology reports2017
Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
Review in Current gastroenterology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of Chinese Herbal Formula Sini Zuojin Decoction in Treating Gastroesophageal Reflux Disease: Clinical Evidence and Potential Mechanisms.Frontiers in pharmacology · 2020Pooled it
- Chronic Cough and Gastroesophageal Reflux in Children: CHEST Guideline and Expert Panel Report.Chest · 2019Guideline
- Integrated network pharmacology and clinical study to reveal the efficacy and tolerability of Huoxue Tongjiang decoction for the treatment of non-erosive reflux disease-related symptoms.Journal of translational internal medicine · 2025Article
- Current pharmacological and procedural treatments for gastro-oesophageal reflux disease: comprehensive review.BJS open · 2025Review
- The role of an anti-reflux diet in the treatment of chronic cough caused by laryngopharyngeal reflux.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Observational
- Diagnosis and Management of Gastroesophageal Reflux Disease: Current Insights.Clinical and experimental gastroenterology · 2025Review
- Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Observational
- Combined contributions of cytochrome P450s (CYPs) and non-enzymatic metabolism in the in vitro biotransformation of anaprazole, a novel proton pump inhibitor.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways.Molecular medicine (Cambridge, Mass.) · 2022Article
- Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option?Therapeutic advances in gastroenterology · 2022Article
- Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2020Review
- Why differences between New York and New Delhi matter in approach to gastroesophageal reflux disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Article
- Alginates: From the ocean to gastroesophageal reflux disease treatment.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- Zhujie Hewei Granules Ameliorated Reflux Esophagitis in Rats.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Article
- Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewProton pump inhibitor (PPI) use in gastroesophageal reflux disease (GERD) has been redefined, in light of recent advances highlighting GERD phenotypes that respond to PPIs, and fresh revelations of potential risks of long-term PPI therapy. RECENT
findingsErosive esophagitis predicts excellent response to PPI therapy, but non-erosive reflux disease (NERD) with abnormal reflux parameters on ambulatory reflux monitoring also demonstrates a similar response. In contrast, response is suboptimal in the absence of abnormal reflux parameters. In this setting, if an alternate appropriate indication for PPI therapy does not coexist, risks may outweigh benefits of PPI therapy. Adverse events from long-term PPI therapy continue to be reported, most based on association rather than cause-and-effect. Appropriate indications need to be established before embarking on long-term PPI therapy. Future research will define true risks of long-term PPI therapy, and develop alternate management options for acid peptic diseases.
Indexed as
Identifiers
28780717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.